Selected article for: "cardiovascular disease and continuous variable"

Author: Morin, Daniel P.; Manzo, Marc A.; Pantlin, Peter G.; Verma, Rashmi; Bober, Robert M.; Krim, Selim R.; Lavie, Carl J.; Qamruddin, Salima; Shah, Sangeeta; Soto, José D. Tafur; Ventura, Hector; Price-Haywood, Eboni G.
Title: Impact of Pre-Infection Left Ventricular Ejection Fraction on Outcomes in COVID-19 Infection: Ejection Fraction and COVID Outcomes
  • Cord-id: b3vuszsd
  • Document date: 2021_3_19
  • ID: b3vuszsd
    Snippet: BACKGROUND: Coronavirus disease 2019 (COVID-19) has high infectivity and causes extensive morbidity and mortality. Cardiovascular disease is a risk factor for adverse outcomes in COVID-19, but baseline left ventricular ejection fraction (LVEF) in particular has not been evaluated thoroughly in this context. METHODS: We analyzed patients in our state's largest health system who were diagnosed with COVID-19 between March 20 and May 15, 2020. Inclusion required an available echocardiogram within on
    Document: BACKGROUND: Coronavirus disease 2019 (COVID-19) has high infectivity and causes extensive morbidity and mortality. Cardiovascular disease is a risk factor for adverse outcomes in COVID-19, but baseline left ventricular ejection fraction (LVEF) in particular has not been evaluated thoroughly in this context. METHODS: We analyzed patients in our state's largest health system who were diagnosed with COVID-19 between March 20 and May 15, 2020. Inclusion required an available echocardiogram within one year prior to diagnosis. The primary outcome was all-cause mortality. LVEF was analyzed both as a continuous variable and using a cutoff of 40%. RESULTS: Among 396 patients (67±16 years, 191 [48%] male, 235 [59%] Black, 59 [15%] LVEF ≤40%), 289 (73%) required hospital admission, and 116 (29%) died during 85±63 days of follow-up. Echocardiograms, performed a median of 57 (IQR 11-122) days prior to COVID-19 diagnosis, showed a similar distribution of LVEF between survivors and decedents (p=0.84). Receiver operator characteristic analysis revealed no predictive ability of LVEF for mortality, and there was no difference in survival among those with LVEF ≤40% vs. >40% (p=0.49). Multivariable analysis did not change these relationships. Similarly, there was no difference in LVEF based on whether the patient required hospital admission (56±13 vs. 55±13, p=0.38), and patients with a depressed LVEF did not require admission more frequently than their preserved-LVEF peers (p=0.87). A premorbid history of dyspnea consistent with symptomatic heart failure was not associated with mortality (p=0.74). CONCLUSIONS: Among patients diagnosed with COVID-19, pre-COVID-19 LVEF was not a risk factor for death or hospitalization.

    Search related documents:
    Co phrase search for related documents
    • Try single phrases listed below for: 1